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Abstract 
Molecules that inhibit DNA dependent processes are the most commonly used agents for 
the treatment of cancer.  The genotoxicity associated with their mechanisms of action, 
unfortunately, make them extremely toxic to the patient and cancer cells alike.  The work 
presented in this thesis outlines the development of Py-Im polyamides as non-genotoxic DNA-
targeted antitumor molecules that interfere with RNA polymerase II elongation.  We initially 
characterized the pharmacokinetic profiles of two hairpin polyamides to establish their 
bioavailability in the serum and tissues after a single administration.  We next determined the 
molecular mechanism that contributes to toxicity of a hairpin polyamide in human prostate 
cancer cells in cell culture and we demonstrated antitumor effects of the compound against 
LNCaP xenografts in mice.  Finally, we conducted animal toxicity experiments on 4 polyamides 
that vary on the -turn with respect to the substitution of amino and acetamide groups at the  
and  positions.  From this study we identified a second generation compound that retains 
antitumor activity with significantly reduce animal toxicity.  This work sets the foundation for 
the development of Py-Im polyamides as DNA targeted therapeutics for the treatment of 
advanced prostate cancer. 
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Introduction: DNA as a therapeutic target in cancer 
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1.1 Background and significance. 
The human genome consists of approximately 20,000 protein coding genes and many 
more genes that encode non-coding RNA with crucial cellular functions.(1) The 
regulatory networks that govern gene expression are immensely complex and work 
cooperatively to control cellular function and cellular response to environmental stimuli.  
It is due to this intricate regulation of gene expression that cells of the same genetic 
material can differentiate into various phenotypes in the human body to perform 
specialized tasks.  
As a result of numerous DNA dependent processes, corruption to the DNA code can 
result in aberrant cellular behavior.(2)  Thus, essential DNA dependent processes such as 
transcription and replication participate in DNA damage repair to ensure genomic 
stability.(3, 4) (Fig. 1.1)  Transcription coupled nucleotide excision repair (TC-NER) is a 
mechanism that relies on elongating RNA polymerase II (RNAP2) to identify lesions or 
blockages in the DNA.  Once the RNAP2 holoenzyme encounters a blockage on the 
transcribed DNA strand it recruits the proteins CSA, CSB, XAB2, and HMGN1 to repair 
the DNA lesion.  If the DNA damage cannot be repaired, persistent blockage to RNAP2 
elongation will trigger p53 dependent and independent apoptosis.(3, 5-8)   Similarly, 
DNA lesions are recognized by replicating DNA polymerase in the S phase.(4)  If the 
lesion cannot be repaired, persistent block to replication will also trigger cell death.  
While most instances of DNA damage are efficiently repaired, some escape as mutations 
and are retained in the genetic code.  Over time these mutations accumulate and cause 
altered patterns of gene expression, which ultimately lead to genetic diseases like cancer. 
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1.2 DNA as a target for cancer therapy. 
As the underlying source of cancer, some of the oldest and most effective anticancer 
agents are targeted to the DNA.  Historically, the development of DNA targeted 
chemotherapeutics began as circumstantial observation to the side effects of chemical 
warfare during World War II.(9)  Physicians examining sailors exposed to mustard gas, 
after a shipment of M47A1 mustard gas bombs leaked from the damaged SS John 
Harvey, noticed signs of lymphoid and myeloid suppression.(10)  It was reasoned that the 
high proliferation rate of bone marrow cells made them susceptible to the alkylating 
effects of mustard gas, thus cancers with similarly high proliferations rates, such as 
leukemias and lymphomas, may also be targeted by such agents.(11)  In a clinical study 
by Goodman et al. in 1946, it was found that treatment with nitrogen mustards indeed 
caused remission in patients with lymphoma.(12) 
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The utility of alkylating agents for the treatment of lymphoma opened the way for the 
development of new DNA targeted agents with novel mechanisms.(13, 14) (Table 1.1)   
Many of these drugs form covalent interstrand crosslinks, stabilize protein-DNA 
complexes of topoisomerases I and II, or inhibit DNA and RNA synthesis.(4, 13, 14)  
These modifications to the DNA introduce blockages to many DNA dependent processes 
including transcription and replication, which in turn triggers apoptosis in diseased 
cells.(4, 14-17)  However, because transcription and replication are common to cancerous 
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and normal cells alike, systemic treatment with DNA targeted therapeutics can be very 
toxic to the patient as well. 
1.3 Limitations of DNA targeted therapy. 
Most DNA targeted therapeutics preferentially affect cancerous cells due to their high 
proliferation rate and genomic instability, but benign cells can also be affected.  Normal 
cells can tolerate basal levels of DNA damage generated by exogenous chemicals and by 
by-products of cellular metabolism.  However, the endogenous DNA repair mechanisms 
are often overwhelmed by DNA targeted therapeutics.(18)  Studies of patients treated 
daunomycin and cytarabine shortly after their introduction in the 1960s documented the 
presence chromosomal abnormalities associated with DNA fragmentation in normal 
cells.(19, 20)  The extensive DNA damage caused by chemotherapeutic treatment has 
been linked to the acquisition of resistance towards chemotherapy and the development 
of secondary cancers.(21-23) 
A recent study on the effects of chemotherapy in the tumor microenvironment 
indicates genotoxic stress can cause normal cells to promote tumor survival, which 
further complicates the long term utility of DNA targeted drugs.   In the study by Sun et 
al. treatment of prostate fibroblasts with DNA damaging agents such as bleomycin, 
mitoxantrone, and ionizing radiation was found to activate WNT16B expression in a NF-
B dependent manner.(24)  Interestingly, the expression of WNT16B was not 
significantly increased when prostate cancer cells were treated with the same genotoxic 
agents.  As a secreted signaling protein, WNT16B activates the Wnt expression program 
in tumor cells, which in turn promotes survival and metastasis.   
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As a consequence of the numerous side effects of DNA targeted therapeutics, 
research in the field has waned in favor of therapeutic agents with more specific 
molecular targets and less systemic toxicity.(14)   However, despite their limitations 
DNA targeted therapies remain a staple in most treatment regimens.  Thus, development 
of a new class of DNA targeted molecules, without genotoxic side effects, could 
circumvent the problems associated with current therapies. 
1.4 Noncovalent minor groove binders as anticancer agents. 
DNA minor groove binders consist of molecules that permanently modify DNA in a 
covalent manner and those that interact with DNA noncovalently. The latter group of 
molecules interferes with DNA dependent process in a reversible manner.  This group of 
molecules includes DAPI, pentamidine, berenil, Hoechst, distamycin A, netropsin, and 
their synthetic derivatives.(25)    
Clinically, diarylamidines, consisting of DAPI, pentamidine, and berenil, have been 
used for the treatment of several protozoa related diseases.(26) (Fig. 1.2) The minor 
groove binder DAPI inhibits DNA and RNA polymerases by binding to A/T rich tracts of 
DNA.(27-30)  While DAPI is active against Trypanosome Congolese, undesirable side 
effects have limited its clinical use.  Pentamidine is clinically used to treat infections of 
Trypanosoma brucei gambiense, Leismania donovani, and Pneumocystis carinii.  Berenil 
is used to treat trypanosomiasis in veterinary medicine.(25)  
Bisbenzimidazoles are Hoechst-like compounds that bind to A/T rich DNA 
sequences.(31, 32) (Fig. 1.2)  They have been shown to interfere with DNA dependent 
process in cell culture without causing DNA damage.(33)  Furthermore, a symmetric 
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bisbenzimidazole has demonstrated antitumor activity against  CH1 human ovarian 
carcinoma xenografts in vivo.(34)  
Distamycin A and netropsin are tripyrrole and dipyrrole oligomers, respectively, and 
bind to A/T tracts.  Both compounds bind to the minor groove in a 1:1 fashion.(35, 36)  
(Fig. 1.2) Distamycin has been shown to also bind in a 2:1 manner.(37)  Similar to other 
noncovalent minor groove binders, these compounds inhibit DNA and RNA 
polymerases.(6, 28, 38) 
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 Py-Im polyamides are synthetic oligomers based on the structures of distamycin A 
and netropsin.  Research in the Dervan lab have improved the DNA binding affinity of  
polyamides by linking two oligomers with a turn unit and enforcing 2:1 binding as a 
hairpin.(39)  Sequence recognition by polyamides has also been expanded by 
incorporation of new aromatic heterocycles that discriminate between A/T and G/C base 
pairs through the antiparallel pairing of these amino acids.(40, 41) (Fig. 1.3) 
Additionally, conjugation of fluorescein or isophthalic acid to the C-terminal tail of 
polyamides significantly improves their nuclear localization.(42, 43)  
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 Historically, these compounds were found to exhibit antifungal activity in yeast 
through a DNA dependent mechanism that did not cause genotoxicity.(44)  In cell 
culture, Py-Im polyamides are able to regulate gene expression in inducible transcription 
systems(45-49), and are toxic to a variety of cancer cell lines.(50)  Animal experiments 
have shown Py-Im polyamides are bioavailable through multiple forms of 
administration(51-55), and can affect gene expression in target tissues in vivo.(56, 57) 
These characteristics make Py-Im polyamides ideal candidates for development as novel 
DNA targeted therapeutics. 
1.5 Scope of this work. 
The work presented here focuses on the characterization of Py-Im polyamides as non-
genotoxic antitumor agents that are active against prostate cancer xenografts.  Chapter 2 
details the pharmacokinetic and animal toxicity analysis of two hairpin polyamides 
targeted to the 5’-WGWWCW-3’ sequence found in the androgen response element.  In 
this study it was found that the polyamide with an α amino turn was much less toxic to 
animals than the compound with a β acetamide turn.(55)  The less toxic polyamide is 
further characterized in chapter 3 as a non-genotoxic DNA binder that interferes with 
RNAP2 elongation, and causes cell death in  human prostate cancer cells  in cell culture 
and in xenografts.(58)  Chapter 4 revisits the difference in rodent toxicity that stems from 
the -turn.  By using 4 polyamides that vary at the turn (α amino, β amino, α acetamide, 
and β acetamide), we assessed differences in animal toxicity and determined the target 
organs of pathology.  From this study we identified a structural analog to the parent 
compound that retains antitumor activity without causing animal toxicity. 
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Abstract 
Pyrrole-Imidazole (Py-Im)  polyamides are programmable, sequence specific 
DNA minor groove binding ligands.  Previous work in cell culture has shown that various 
polyamides can be used to modulate the transcriptional programs of oncogenic 
transcription factors.  In this study two hairpin polyamides with demonstrated activity 
against androgen receptor signaling in cell culture were administered to mice to 
characterize their pharmacokinetic properties. Py-Im polyamides were administered 
intravenously by tail vein injection.  Plasma, urine, and fecal samples were collected over 
a 24hr period.  Liver, kidney, and lung samples were collected postmortem.  
Concentrations of the administered polyamide in the plasma, excretion, and tissue 
samples were measured using LC/MS/MS.  The biodistribution data were analyzed by 
both non-compartmental and compartmental pharmacokinetic models.  Animal toxicity 
experiments were also performed by monitoring weight loss after a single subcutaneous 
(SC) injection of either polyamide. The biodistribution profiles of both compounds 
exhibited rapid localization to the liver, kidneys, and lungs upon injection.  Plasma 
distribution of the two compounds showed distinct differences in the rate of clearance, 
the volume of distribution, and the AUCs.  These two compounds also have markedly 
different toxicities after SC injection in mice. The variations in pharmacokinetics and 
toxicity in vivo stem from a minor chemical modification that is also correlated to 
differing potency in cell culture.  The results obtained in this study could provide a 
structural basis for further improvement of polyamide activity both in cell culture and in 
animal models. 
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2.1   Introduction 
The development of new DNA-targeted therapeutics is a promising frontier in the 
treatment of human disease.  Py-Im polyamides are peptides of cyclic aromatic amino 
acids whose anti-parallel pairing confers sequence specific binding to the DNA minor 
groove [1-4].  Members of this class of compounds have been used to modulate gene 
expression programs in cell culture [5-13] and affect tumor growth in animal models [14-
16]. 
Recently, a series of Py-Im polyamides have been developed to disrupt androgen 
receptor (AR) signaling [5, 6, 11], presenting an alternative strategy for therapeutic 
intervention in prostate cancer.  These compounds were designed to bind to a 5’-
WGWWCW-3’ sequence contained within the consensus androgen response element 
(ARE) to prevent AR protein-DNA interactions.  Cell culture experiments of LNCaP 
prostate cancer cells co-treated with dihydrotestosterone (DHT) and ARE-targeted 
polyamides have shown decreased expression of several AR driven genes such as PSA, 
KLK2, and TMPRSS2 when compared to samples treated with DHT alone.  Polyamide 1 
inhibited DHT-induced genes in a dose dependent manner ranging from 0.74 g/mL to 
7.4 g/mL, with 7.4 g/mL being the most active concentration [11].  Polyamide 2 
contains a minor structural modification where the (R)-2,4-diaminobutyric acid turn of 1 
is replaced with an acetylated (R)-3,4-diaminobutyric acid.  Due to this modification, 
polyamide 2 was found to have equivalent activity to 1 at 10 fold less concentration 
without significant changes to its DNA binding ability [6, 8, 11]. 
While the pharmacokinetics of other Py-Im polyamides have been published 
previously [17-20], the PK profiles of these structurally distinct ARE-targeted hairpin 
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polyamides have never been explored. For this study, mice were chosen as the preclinical 
model for the determination of polyamide concentrations in plasma, liver, kidney, and 
lung. In addition, urinary and fecal levels were measured to assess the relative importance 
of these routes of drug elimination. The data presented here represent the first detailed 
description of the in vivo pharmacokinetic and toxicological study of these molecules.  
2.2 Materials and Methods 
Chemicals and Reagents.  Acetonitrile (ACN) and methanol (MeOH) were of HPLC-
grade and purchased from Fisher Scientific (Fair Lawn, NJ, USA). Glacial acetic acid 
(ACS grade) was purchased from J.T. Baker (Phillipsburg, NJ, USA). Formic acid (99% 
pure) was from Acros organic (New Jersey, USA). Water was purified using the 
Millipore Milli-Q system (Milford, MA, USA). Mouse plasma for preparation of 
standards and quality controls (QC) were obtained from The City of Hope Medical 
Center Animal Center.  Py-Im polyamides 1 - 4 were synthesized by solid phase 
synthesis as previously described [21, 22].  For structures of internal standards (INS) 3 
and 4 see Fig. S2.1. 
Animals for pharmacokinetic studies.  Py-Im polyamide pharmacokinetic studies were 
performed in 10-12 week old female BALB/C mice (Charles River).  Polyamides were 
solubilized in PBS (1) or PBS/DMSO (2) and administered via intravenous (IV) tail vein 
injection at concentrations of 7.5mg/kg and 5mg/kg, respectively.  For each experiment, 
groups of 3 animals were euthanized at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours after 
injection. Animals designated for the 4, 8, and 24 hour timepoints were housed in 
metabolic cages for collection of urine and feces as described below. All animal used in 
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the pharmacokinetic experiments were performed under an approved protocol at the City 
of Hope. 
Animals for toxicology studies.  Toxicities of polyamides 1 and 2 were measured after 
SC injections in 8-12 week old female C57BL/6 mice (Jackson Laboratory).  In 
anticipation of future xenograft experiments, subcutaneous injection, which has been 
shown to be a viable route of polyamide delivery [20], was chosen as the desired delivery 
method.  A single bolus of polyamide 1 or 2 in PBS/DMSO vehicle was given, and the 
animals were weighed daily and monitored closely for signs of duress for 7 days.  
Animals exhibiting >15% weight loss or signs of distress were euthanized according to 
regulations outlined by IACUC.  Four animals were used in each group unless otherwise 
noted. This toxicology study was performed under an approved protocol at the California 
Institute of Technology. 
Analytical methods development.  Concentrations of polyamides 1 and 2 were analyzed 
by LC/MS/MS using a Waters Acquity UPLC system (Milford, MA, USA) interfaced 
with a Waters Quattro Premier XE Mass Spectrometer.  HPLC separation was achieved 
using a Jupiter 4u Proteo 90A 150x2.0 mm column (Phenomenex, Torrance, CA, USA) 
proceeded by a Phenomenex C8 guard column (Torrance, CA, USA).  The column 
temperature was maintained at 30oC.  The mobile phase consisted of A (0.05% acetic 
acid in water) and B (0.05% acetic acid in acetonitrile).  The following gradient program 
was used: 8% B (0-1 min, 0.3 ml/min), 16% B (3 min, 0.3 ml/min), 58% B (6 min, 0.3 
ml/min), 90% B (7 min, 0.3 ml/min), 8% B (7.3 min, 0.3 ml/min).  The total run time was 
11.5 minutes.  The auto-injector temperature was maintained at 5oC.  The strong needle 
wash solution was 5% formic acid in MeOH:ACN (2:8) for both compounds, and the 
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weak needle wash solution was 30% MeOH in water for compound 1 and 50% ACN in 
water for compound 2.  The electrospray ionization source of the mass spectrometer was 
operated in positive ion mode with a cone gas flow of 50 L/hr and a desolvation gas flow 
of 700 L/hr. The capillary voltage was set to 3.2 kV, and the cone and collision cell 
voltages were optimized to 32 V and 27 V for 1 and the INS 3.  Voltages were optimized 
to 31 V and 20 V for 2 and the INS 4.  The source temperature was 125oC and the 
desolvation temperature was 470oC. A solvent delay program was used from 0 to 4.0 
minutes and from 6.1 to 11.5 minutes to minimize the mobile phase to flow to the source. 
MassLynx version 4.1 software was used for data acquisition and processing. 
Positive electrospray ionization of all compounds produced abundant protonated 
molecular ions (M+3H) 3+. The fragmentations of these compounds were induced under 
collision induced dissociation condition. The precursorproduct ion combinations at m/z 
453.52206.10 for 1, 454.85210.24 for 3, 467.45238.32 for 2, and 469.9238.4 
for 4 were used in multiple reaction monitoring (MRM) mode to determinate these 
compounds. The use of MRM provided sufficient specificity and sensitivity. MS/MS 
experimental conditions, such as collision energy and collision cell pressure, were 
optimized from continuous flow injection sample introduction of standard solutions. 
Under optimized assay conditions, the retention times for 1 and 3 were 5.0 min, and 5.5 
min for 2 and 4. 
Plasma sample preparation.  Plasma and urine samples were prepared for LC/MS/MS 
analysis by mixing 30 L of plasma with 20 L of 50% MeOH and 50% aqueous 1% 
HOAc.  The mixture was vortexed and mixed with an additional 120 L of 0.5% HOAc 
in MeOH:ACN (4:6) and 20 L of 6.0 g/mL INS in MeOH:1% aqueous HOAc (1:1).  
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The mixture was vortexed again for 2 minutes and centrifuged at the highest setting for 4 
minutes.  Next, 20 L of the supernatant was transferred to a new tube and mixed with 
180 L of 50% MeOH:ACN (4:6) and 50% aqueous 1% HOAc. 
Standard curves were prepared mixing untreated plasma with 20 L of 50% 
MeOH and 50% aqueous 1% HOAc prepared with various concentrations of 1 and 2.  
Internal standards were added as described above.  The standard curves, as determined by 
linear regression, displayed good linearity (r2 > 0.99) over the range tested for 1 (0.1 
g/mL to 30 g/mL) and 2 (0.2 g/mL to 20 g/mL). 
Urine and Fecal sample preparation.  Urine and fecal samples were collected using 
metabolic cages (Ancare, Techniplast Metabolic Rack, 12 cages by Nalgene).  Urine 
samples were collected at 3 time points over 24 hr and fecal samples were collected at 8 
hr and 24 hr time points.  Py-Im polyamides were extracted from urine according to the 
plasma extraction procedure described above. 
Fecal samples were first dried at room temperature and then weighed and 
grounded to a powder. Approximately 100mg of powder was weighed out and 
reconstituted in distilled water (6 µL/mg powder). The fecal sample was then 
homogenized in a TissueLyser (Qiagen) for 2 minutes at 30Hz twice, and an additional 6 
µL/mg of distilled water was added.  Next, 30 µL of the fecal homogenate was mixed 
with 50 µL distilled water and 20µL of 50% MeOH and 50% aqueous 1% HOAc.  The 
mixture was then vortex mixed with 0.1 mL 0.5% HOAc in MeOH:ACN (2:8) and 20 µL 
of 6.0 µg/mL INS in MeOH:1% aqueous HOAc (1:1) for 10 minutes  and centrifuged at 
the highest setting for an additional 10 minutes.  The supernatant was diluted with 50% 
MeOH:ACN (4:6) and 50% aqueous 1% HOAc. 
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Tissue sample preparation.  Distribution of polyamides 1 and 2 was determined in the 
liver, kidneys, and lungs.  The organs were harvested post-euthanasia and prepared via 
similar processes.  A piece of the mouse organ was weighed and mixed with distilled 
water (3 µL/mg tissue).  The tissue was then homogenized by pulsing three times on a 
TissueLyser for 2 minutes each at 30Hz.  Next, 30 µL of the tissue homogenate was 
mixed with 20 µL of 50% MeOH and 50% aqueous 1% HOAc.  The mixture was then 
vortex mixed with 0.12 mL 0.5% HOAc in MeOH:ACN (2:8) and 20 µL of 6.0 µg/mL 
INS in MeOH:1% aqueous HOAc (1:1) for 10 minutes  and centrifuged at the highest 
setting for an additional 10 minutes. Samples treated with polyamide 1 were then diluted 
with 50% MeOH:ACN (4:6) and 50% aqueous 1% HOAc.  Samples treated with 
polyamide 2 were diluted with 50% MeOH:ACN (4:6) and 50% aqueous 3% FA. 
Pharmacokinetic Data Analysis.  Plasma pharmacokinetic parameters were derived 
from polyamide concentration profiles using both non-compartmental and compartmental 
methods.  Non-compartmental analysis was performed according to statistical moment 
theory and the rule of linear trapezoids, while compartmental analysis was performed in 
ADAPT II [24].  Pharmacokinetic parameters estimated from the non-compartmental 
analysis include the maximum concentration (Cmax), the terminal elimination half-life 
(t1/2), the mean residence time (MRT), the area under the concentration curve (AUC0-
24h), the AUC extrapolated to infinity (AUC0-inf), and the clearance (CL). Additional 
plasma pharmacokinetic parameters determined from the compartmental analysis include 
the alpha and beta half-lives (t1/2) and the apparent volume of distribution (Vd) Tissue 
pharmacokinetic parameters were determined non-compartmentally and included the 
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Cmax and AUC0-24h. Urinary and fecal excretion data were expressed as the cumulative 
percentage of the administered dose. 
pH Stability Analysis.  The pH stability of Py-Im polyamides were analyzed as 
previously described [23].  In summary, 15 L of a 10 M solution of polyamide 1 or 2 
in DMSO were incubated with 85 L of buffer with pH of 2.5, 4, 7, or 10 (Fluka) at 37 
oC for 24 hr.  After incubation the sample were mixed with an equal volume of N,N-
dimethylformamide and sonicated briefly.  Next 20 L of the sample solution was mixed 
with 180 L of aqueous buffer containing 100 mM NH4OAc and 25 M methyl 4-nitro-
1H-pyrrole-2-carboxylate as an internal standard.  Analytical HPLC analysis was 
performed on a Beckman analytical HPLC. 
 
2.3 Results 
Plasma Distribution.  The structures and plasma concentration profiles of polyamides 1 
and 2 are shown in Fig. 2.1 and the pharmacokinetic parameters calculated non-
compartmentally and using a 2-compartment model are summarized in Table 1.  Plasma 
concentrations for both polyamides were well above the lower limit of quantification over 
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the entire time course. The average Cmax was 49.4±11.2 µg/mL (mean±S.D., n=3) for 1 
and 41.3±5.9 µg/mL for 2. Both compounds exhibited a bi-exponential pattern of decay 
with first-order elimination, with initial and terminal t1/2’s of 0.5 and 4.6 hours for 1, and 
0.1 and 4.2 hours for 2. The average concentrations of 1 and 2 24 hours post injection 
were 0.21±0.1 µg/mL and 0.49±0.2 µg/mL, respectively.  
 
Despite using a higher dose, the AUC of 1 was 2-fold lower than 2 (67.5 versus 
144.8 g/mLxhr). Furthermore, the Vd of 1 was 2-fold higher than 2 (8.1 versus 4.0 mL). 
The calculated CL of 1 was 3-fold higher than 2 (2.1 versus 0.7 mL/hr).  
Urine and Fecal Excretion.  Concentration profiles of polyamides 1 and 2 in urine are 
shown in Fig. 2.2a. The urinary excretion of polyamide 1 was nearly complete by 4 hours, 
with a cumulative excretion of 5.7±2.9% of the administered dose. Urinary excretion of 
polyamide 2 was much more extensive and continued throughout the entire time course, 
with a cumulative urinary excretion at 24 hours of 46.0±15.2% of the administered dose.    
Fecal recovery at 8 and 24 hours did not yield significant amounts of either 
polyamide, with cumulative recoveries after 24 hours of less than 5% of the administered 
dose (Fig. 2.2b). This finding is consistent with previously published results of a similarly 
sized polyamide [19]. 
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Tissue Distribution.  To examine tissue distribution, several organs previously reported 
to have polyamide localization were analyzed.  Distribution profiles of polyamides 1 and 
2 in the liver are shown in Fig. 2.3a.   Both compounds localized rapidly to the liver post-
administration.  Polyamide 1 reached a maximum concentration of 11.7±1.3 g/g at 5 
minutes post injection.  The concentration of polyamide 2 also peaked 5 minutes after 
injection at a maximum concentration of 43.8±0.7 g/g.  Both polyamides exhibited 
higher retention in the liver tissue than plasma.  At the experiment endpoint 4.8±0.3 g/g 
of 1 and 17.4±8.1 g/g of 2 was found to remain in the liver.  The AUC0-24h of 
polyamide 1 and 2 in the liver were 157.7 and 301.3 g/gxhr, respectively. The 
localization of 1 and 2 to the liver is consistent with previously published positron 
emission tomography (PET) results of a related radiolabeled hairpin polyamide [23].     
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Polyamide pharmacokinetic profile in the kidneys is shown in Fig. 2.3b.  Maximum 
kidney concentration of both polyamides was reached 5 minutes post injection with an 
average Cmax of 27.0±2.9 g/g and 35.1±2.8 g/g for polyamides 1 and 2, respectively. 
As in liver the rate of polyamide elimination from the kidney was slower than from the 
plasma, and the AUC0-24h of polyamides 1 and 2 in the kidney was 299.2 and 424.7 
g/gxhr, respectively.  The increased concentrations of polyamide 2 relative to 1 in 
kidney were consistent with its higher rate of urinary excretion. 
 
Unlike liver and kidney, polyamide concentrations in the lung peaked at 15 
minutes following injection for both compounds (Fig. 2.3c).  The Cmax of polyamide 2 in 
the lung was greater than 15 fold higher than compound 1, with maximum concentrations 
of 256±93.1 g/g for 2 and 16.4±1.4 g/g for 1. After an initial rapid decline, especially 
for polyamide 2, concentrations in the lung were maintained above 2.8±0.2 g/g and 
21.8±7.6 g/g for 1 and 2 respectively over the entire time course. The AUC0-24h of 
polyamide 1 and 2 in the lung were 130.6 and 523.5 g/gxhr, respectively.  Tissue PK 
parameters are summarized in Table 2.2. 
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Compound Stability.  The stability of polyamides 1 and 2 at various physiological pHs 
were explored by incubating in pH 2.5, 4, 7, and 10 buffers at 37oC for 24 hr. Analytical 
HPLC analysis of incubated samples did not display significant signs of degradation at 
any pH.  See Online Resource Fig. S2.2. 
Toxicity Study.  Based on a defined threshold of greater than 15% weight loss over a 7 
day observation period, the toxicity following a single subcutaneous injection of 
polyamide 1 or 2 was determined to be significantly different (Fig. 2.4).  For polyamide 
1, critical weight loss occurred only at the highest dose level 10mg/kg.  However, 
polyamide 2 demonstrated dose-limiting weight loss at both 4.5 mg/kg and 2.3 mg/kg.  
No additional signs of duress were observed in the animals treated with polyamide 1,  
however, animals treated with polyamide 2 at doses of 4.5mg/kg and 2.3 mg/kg exhibited 
multiple signs of duress such as loss of ambulation and hunched posture in addition to 
weight loss. 
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2.4 Discussion 
Py-Im polyamides are sequence-specific DNA minor groove binders that have been 
shown to modulate gene expression regulated by transcription factors of oncological 
importance [10-13].  Of these compounds, two hairpin polyamides developed to disrupt 
AR signaling are of particular interest due to their gene regulation activities [6, 11] and 
potent cytotoxicity towards the LNCaP prostate cancer cell line [25].  While the two 
hairpin polyamides are structurally similar, a minor structural modification on the 
diaminobutyric acid turn was able to confer a ten-fold increase in the ability of polyamide 
2 to downregulate PSA mRNA expression.  In this study pharmacokinetic methods were 
employed to explore the differences in circulation, excretion, and tissue biodistribution of 
these ARE-targeted hairpin polyamides in mice. 
Polyamide distribution in the plasma showed clearance profiles indicative of first-
order elimination for both compounds (Fig. 2.1b and Table 2.1).  This data is in line with 
published PK results of related polyamides in rats [17].  The maximum plasma 
concentration for polyamide 1 was found to be over 3 times the effect dosage for PSA 
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mRNA downregulation in cell culture, while the Cmax for polyamide 2 was found to be 
approximately 29 times the effective concentration.  Analysis of the plasma PK data 
showed that polyamide 2 exhibited a higher systemic exposure and lower clearance rate 
than polyamide 1.  Although the plasma clearance of polyamide 1 was ~3 fold faster than 
polyamide 2 it was not significantly eliminated through the urine or feces.  Polyamide 2, 
however, was largely eliminated through the urine (Fig. 2.2).  The low amount of renal 
and biliary elimination of compound 1 may be suggestive of compound retention in the 
tissues or its metabolic degradation.  A previous absorption, distribution, metabolism, 
excretion, and toxicity (ADMET) study had ascertained that polyamide 2 was resistant to 
liver microsomal degradation [5], however, the microsomal stability of polyamide 1 was 
never examined, and thus enzymatic degradation could be a route of elimination for this 
compound.   
Interestingly, tissue analysis of the liver, kidneys, and lungs showed higher 
concentrations of polyamide 2 than 1 (Fig. 2.3 and Table 2.2).  The three organs analyzed 
here have been previously documented as representative organs of polyamide localization 
[17,23], however, it is likely that the compounds were also taken up and retained in other 
tissues types, and that similar differences between the polyamides may exist in these sites. 
The differences in biodistribution between the two compounds may be attributable to 
differences in solubility. Polyamide 2 is less soluble than 1 in aqueous solutions and 
requires a polar aprotic cosolvent like DMSO for administration.  Because the initial 
distribution of polyamide 2 to lung tissue was more than 15 fold higher than polyamide 1, 
it is possible that compound 2 is precipitating out of solution as it reaches high local 
concentrations when passing through the lung immediately after an intravenous injection.  
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Alternatively, it is possible that polyamide 2 is preferentially taken up and retained by the 
lung tissue itself. This phenomenon has been previously described for many drugs and 
exogenous compounds, and the lungs have been demonstrated to have significant effects 
on the pharmacokinetics of drugs given intravenously [26].  Regardless of the mechanism 
of accumulation, once the concentration of polyamide 2 peaks in the lung, it apparently 
re-distributes unchanged back into circulation as indicated by a second peak in the 
plasma concentration versus time profile. Therefore, rather than being a site for drug 
elimination, the lung is serving as a reservoir for polyamide 2, and merely delays its 
release back into the central compartment.  
In addition to differences in biodistribution, animal toxicity studies also revealed 
major differences between the two compounds.  Weight curve experiments following a 
single SC injection of 1 and 2 showed polyamide 2 to be more toxic (Fig. 2.4).  Animals 
treated with 1 only showed significant weight loss at a dose of 10 mg/kg and no 
additional sign of duress was observed.  In contrast, animals treated with polyamide 2 
exhibited additional signs of physical duress in addition to weight loss at all 
concentrations except 1.1 mg/kg.  Taken together, given its greater potency against the 
expression of select AR driven genes and its higher accumulation in normal tissues, the 
increased toxicity of polyamide 2 is likely due to off-target effects in normal organs.  
However, an alternative explanation for the increased toxicity seen with polyamide 2 
could also be due to its relatively poor aqueous solubility. For example, in tissues where 
high local concentrations of polyamide 2 are achieved (i.e. lung), the compound may 
precipitate in capillaries, resulting in microinfarctions and ischemic tissue injury.    
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 In conclusion, both polyamides 1 and 2 are bioavailable in mice after IV tail vein 
injection, and plasma concentration of both compounds are well above the levels required 
for gene regulation in cell culture.  Although polyamide 2 exhibited more favorable 
plasma PK characteristics, with a higher AUC and slower clearance from plasma, it was 
found to be significantly more toxic to the animals.  This study was the first to explore 
the PK properties of ARE-targeted hairpin polyamides, and it has revealed how a minor 
structural modification can influence the PK and toxicological properties of polyamides, 
thus setting the ground work for future xenograft experiments and providing a potential 
route to improve polyamide design for clinical applications.  
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Abstract 
Many cancer therapeutics target DNA and exert cytotoxicity through the induction of 
apoptosis by DNA damage and inhibition of transcription. We report that a DNA minor 
groove binding hairpin pyrrole-imidazole (Py-Im) polyamide interferes with RNA 
polymerase II (RNAP2) activity in cell culture.  Polyamide treatment activates p53 
signaling in LNCaP prostate cancer cells without detectable DNA damage. Genome-wide 
mapping of RNAP2 binding shows reduction of occupancy preferentially at transcription 
start sites (TSS), while occupancy at enhancer sites are unchanged. Polyamide treatment 
results in a time- and dose-dependent depletion of RNAP2 large subunit RPB1 that is 
preventable with proteasome inhibition. This polyamide demonstrates antitumor activity 
in a prostate tumor xenograft model with limited host toxicity. 
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3.1   Introduction 
Several chemotherapeutics including the anthracyclines and cisplatin exert part of 
their cytotoxicity through the inhibition of transcription (1). Transformed cells often 
require constant expression of anti-apoptotic genes for survival, making transcription 
inhibition a relevant therapeutic strategy in oncology (1, 2). Many radio- and 
chemotherapy treatments that target DNA, including UV irradiation, cisplatin, and the 
topoisomerase inhibitors, introduce obstacles to RNAP2 elongation by generating bulky 
or helix distorting lesions (3-5).  In cell culture experiments, transcription blockade has 
been shown to induce the degradation of the RNAP2 large subunit (RPB1), and function 
as a signal for p53 mediated apoptosis (6, 7).  While many DNA targeted therapeutics 
effectively inhibit transcription and induce apoptosis, clinical treatment with genotoxic 
agents can also damage DNA in normal cells, increasing symptomatic toxicity and 
potentially leading to secondary cancers (8).  The question arises whether high affinity, 
non-covalent DNA-binding ligands offer an approach to transcription inhibition without 
DNA damage.   
Hairpin Py-Im polyamides are synthetic oligomers with programmable sequence 
recognition that bind the minor groove of DNA with high affinity (9). Py-Im polyamide-
DNA binding induces allosteric changes in the DNA helix that can interfere with protein-
DNA interactions (10, 11). Py-Im polyamides have been used as molecular probes in cell 
culture to modulate inducible gene expression pathways (12-14). In rodents, 8-ring 
hairpin Py-Im polyamides circulate in blood for several hours after administration, and 
affect changes in gene expression in tissues (15-17). 
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We have previously reported that polyamide 1 (Fig. 3.1), which targets the 
sequence 5’-WGWWCW-3’ found in the androgen response element, inhibited a subset 
of dihydrotestosterone (DHT) induced genes in LNCaP cells (12). In this paper we 
explore the effects of this polyamide on the RNAP2 transcription machinery.  We find 
that RNAP2 is preferentially reduced from transcription start sites genome-wide without 
significant perturbation at enhancer loci. This is accompanied by proteasome dependent 
degradation of the RNAP2 large subunit RPB1. Polyamide treatment induces p53 
accumulation that is consistent with what is observed for other transcription inhibitors 
that interact with DNA (4, 5), but without evidence of DNA damage. This polyamide 
demonstrates efficacy in vivo against prostate cancer xenografts in mice with limited host 
toxicity. 
 
3.2 Materials and Methods 
Compounds and reagents.  Py-Im polyamides 1, 2 and 3 were synthesized on oxime 
resin as described	(18-20). (R)-MG132 (MG132) was from Santa Cruz Biotechnology. 
Cell viability assays.  LNCaP cells were plated in clear bottom 96 well plates at 5,000-
7,500 cells per well.  The cells were allowed to adhere for 24-36h before compounds 
were added in fresh media.  Cell viability was determined by the WST-1 assay (Roche) 
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for 1 and 2 after 24 h or 72 h incubation with cells.  Cells in cytotoxicity rescue 
experiments were treated with 2 alone or with 3M for 24h.  For cell cycle arrest 
experiments LNCaP cells were seeded at 2,500-5,000 cells per well in normal media and 
allowed to adhere for 24-36h.  The media was replaced with media supplemented with 
0.5% FBS and incubated for 48h prior to treatment with compound. 
In vivo xenografts experiments.  All mice experiments were conducted under an 
approved protocol by the Institutional Animal Care and Use Committee of the California 
Institute of Technology.  Male NOD scid gamma (NSG) mice were purchased from The 
Jackson Laboratory.   The animals were individually caged and maintained on a standard 
light-dark cycle.  NSG mice were engrafted with LNCaP cells (2.5 million cells) in a 
mixture of 1:1 media and matrigel in the left flank.  Tumors were grown to ~100mm3 
(LxW2) before beginning treatment with compound or vehicle.  Py-Im polyamide 1 was 
administered once every 3 days in a 5% DMSO:PBS vehicle solution until the 
experiment endpoint.  
Serum measurements. To investigate if polyamide 1 could be detected in peripheral 
blood after SC injections, 120nmol of 1 (in 5% DMSO/PBS) was injected into the right 
flank of four C57BL/6 mice. Blood was collected from anesthetized mice via retroorbital 
collection at 5 minutes, 4 h, and 12 h after injection, then processed by methods 
previously described and analyzed by HPLC	 (21). For measurement of serum PSA 
(KLK3) and uric acid, blood was collected from anesthetized mice via retroorbital 
collection at experimental endpoint and serum was separated from blood by 
centrifugation. Serum PSA (KLK3) was measured by ELISA (R&D systems) according 
to manufacturer’s instructions. Uric acid was measured as described	(22). 
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Chromatin immunoprecipitation. Genomic occupancy of RNA polymerase II was 
determined by chromatin immunoprecipitation (ChIP) with the 4H8 antibody (Abcam).  LNCaP 
cells were plated at 35 million cells per plate in RPMI supplemented with 10% CTFBS and 
allowed to adhere for 24-36 h.  The cells were treated with compound 1 in fresh media (10% 
CTFBS) for 48h.   Cells treated and untreated with 1 were incubated with 1nM DHT for 6h.   
Two step crosslinking was performed as previously described	 (23). After DSG removal, 
chromatin was immunopreciated by previously published methods	 (24).  DNA was harvested by 
phenol chloroform extraction and purified with the QIAquick purification kit (Qiagen).  
Quantitative PCR was used to validate enrichment at the GAPDH transcription start site (Primers: 
F-	 GGTTTCTCTCCGCCCGTCTT , R-TGTTCGACAGTCAGCCGCAT) compared to an 
internal negative locus (Primers: F-TAGAAGGGGGATAGGGGAAC, R-
CCAGAAAACTGGCTCCTTCTT).  Each sample was immunoprecipated as 5 technical 
replicates. The 3 most consistent samples were combined and submitted for sequencing on an 
Illumina genome analyzer. Biological replicates were acquired. 
Data processing and analysis.  Sequencing reads were trimmed down to 36bp and then 
mapped against the male set of human chromosomes (excluding all random 
chromosomes and haplotypes) using the hg19 version of the human genome as a 
reference. Bowtie 0.12.7 was used for aligning reads	(25), with the following settings: "-v 
2 -t --best --strata". Signal profiles over genomic locations were generated using custom 
written python scripts; the refSeq annotation was used for gene coordinates. Enhancers 
and promoters were defined using previously published histone marker data	(26). ChIP-
seq peaks were called using MACS2 with default settings	(27).	Enhancers were defined 
as H3K4me1-positive regions that did not intersect with H3K4me3-positive regions and 
promoters as H3K4me3-positive regions that did not intersect with H3K4me1-positive 
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regions.  Clustering was performed with Cluster 3.0	(28)	and visualized with Java 
TreeView	(29). 
Comet Assay.  LNCaP cells were plated at 1million cells per 10cm plate and allowed to 
adhere for 24 to 36h.  Cells were then incubated with either 10M 1 for 48h or 5M 
doxorubicin for 4h.  DNA damage was assayed using the Trevigen CometAssay® system 
and samples were prepared from harvested cells according to the manufacture protocol.  
Comets were imaged on a confocal microscope (Exciter, Zeiss) at 10x magnification.  
Percentage of DNA in the tail was determined using Comet Assay Lite IV (Perceptive 
Instruments).  More than one hundred comets were scored for each condition. 
Immunoblot assay.  Samples for immunoblot analysis were prepared by plating LNCaP 
or DU145 cells at 1million cells per 10 cm plate.  Cells were allowed to adhere for 24-
36hr prior to incubation with compound.  After the appropriate incubation time cells were 
washed once with ice cold PBS and harvested in ice cold 125L lysis buffer (50mM Tris-
HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X100) containing protease inhibitor 
cocktail (Roche), 1mM PMSF (Sigma), and phosphatase inhibitors (Sigma).  Samples 
were allowed incubate on ice for 10min with vortexing once every 3min.  Cellular debris 
was pelleted by spinning at 14,000rpm for 15min to collect the supernatant.  Samples 
were then quantified for protein content with the Bradford assay (Bio-rad) and boiled 
with 4x sample buffer (Li-Cor) for 5min.  Protein electrophoresis was performed in 4-
20% precast Tris glycine SDS gels (Bio-rad) and transferred to PVDF membranes.  
Membrane blocking was done with Odyssey Blocking Buffer (Li-Cor).   The following 
antibodies used to probe changes in protein levels or phosphorylation states: RBP1 (Santa 
Cruz Biotechnology, N20), p53 (Santa Cruz Biotechnology, DO1), phospho-Chk2-Thr68 
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(Cell Signaling Technology), Phospho-p53-Ser15 (Cell Signaling Technology), 
phosphor-H2A.X-Ser139 (Cell Signaling Technology), phosphor-ATM-Ser1981 
(Abcam), phosphor-DNA-PKcs-Ser2056 (Abcam), and β-actin (Abcam).  Near-IR 
secondary antibodies (Li-Cor) were used for imaging.  Experiments were performed in 
biological replicates. 
Flow cytometry.  To determine cell cycle distribution of LNCaP cells grown in normal 
media or under serum starved conditions 1million cells were seeded to each 10cm plate 
and allowed to adhere for 24 -36h.  Media was then replaced with fresh normal media 
(10% FBS) or serum starved media (0.5% FBS) and incubated for an additional 48h.  
Cells were then trypsinized and prepared for analysis as previously described	 (30). 
Samples were analyzed in biological triplicate on a FACSCalibur (Becton-Dickinson) 
instrument. Data analysis was performed using FlowJo 7.6.5. 
Quantitative RT-PCR.  RNA was extracted using RNEasy columns (Qiagen) according 
to manufacturer’s protocols. cDNA was generated from RNA by reverse transcriptase 
(Transcriptor First Strand cDNA kit, Roche). Quantitative real-time RT–PCR was 
performed using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300 
instrument. mRNA was measured relative to ß glucuronidase as an endogenous control. 
For primer sequences see Table S3.1.  
Confocal microscopy.  Cells were plated in 35mm optical dishes (MatTek) and dosed 
with polyamide 3 at 2μM for 24 h with or without 3μM MG132. Cells were then washed 
with PBS and imaged on a confocal microscope (Exciter, Zeiss) using a 63x oil 
immersion lens. Confocal imaging was performed following established protocols	(18). 
Histology and immunohistochemistry.  Tumors were resected immediately after 
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euthanasia and fixed in neutral buffered formalin. Selected samples were embedded in 
paraffin, sectioned and stained with hematoxylin and eosin (H&E). Selected sections 
were assessed by deoxynucleotidyltransferase dUTP nick-end labeling (TUNEL) as 
described	(31). 
Thermal denaturation assays.  Polyamides 1 and 2 were incubated with duplex DNA 
5’-CGATGTTCAAGC-3’, which contains the predicted target site for these compounds 
(underscore). Melting temperature analyses were performed on a Varian Cary 100 
spectrophotometer as described	 (32). Melting temperatures were defined as a maximum 
of the first derivative of absorbance at 260 nm over the range of temperatures. 
Statistical analysis.  Statistical significance was calculated using the student’s t test with 
two tailed variance.  Results were considered significant when p < 0.05. 
3.3 Results 
The effects of polyamide 1 on global occupancy of RNAP2. Polyamide 1 was 
previously shown to inhibit the induction of a subset of DHT driven genes in LNCaP cell 
culture (12). We interrogated the effects of 1 on the RNAP2 transcription machinery by 
mapping the global occupancy of RNAP2 using ChIP-seq.  Under DHT induction, select 
androgen receptor (AR) driven genes, such as KLK3, showed increased RNAP2 
occupancy over genic regions, which was decreased in the presence of 1 (Fig. 3.2A).  
While RNAP2 occupancy across constitutively expressed genes such as GAPDH did not 
change with DHT induction, cotreatment with 1 reduced RNAP2 occupancy across these 
genes (Fig. 3.2B).  This reduction in RNAP2 occupancy by 1 was in the context of a 
global decrease of RNAP2 occupancy across genic regions (Fig. S3.1), particularly at 
transcription start sites (TSS) (Fig. 3.2C).  However, 1 did not significantly change 
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RNAP2 occupancy at enhancer loci (Fig. 3.2D), suggesting 1 may affect the active 
elongation of RNAP2 without disturbing the transcription apparatus anchored at 
enhancers, and that the observed differences in RNAP2 occupancy are not due to 
technical variation in ChIP success between experiments.  Reduction in DNA occupancy 
of RNAP2 has also been reported in cells treated with α-amanitin, a cyclic octapeptide 
inhibitor of RPB1 (33).   
 
Inhibition of RNAP2 elongation can be caused by a multitude of genotoxic agents and 
often results in the degradation of the RPB1 subunit (3, 34, 35). Indeed, in addition to 
reduced RNAP2 DNA occupancy, immunoblot analysis of LNCaP cells treated with 1 
shows depletion of RPB1 in a time- and concentration-dependent manner (Fig. 2E).  To 
examine if the effects of RPB1 degradation was transcription dependent we measured 
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levels of RPB1 mRNA (Fig. 2F).  The expression of RPB1 modestly increased with 
polyamide treatment, suggesting this depletion is post-transcriptional.  
Polyamide cytotoxicity is reduced by proteasomal inhibition and serum starvation. 
Inhibition of RNAP2 has been reported to induce apoptosis (4, 6, 36), and may contribute 
to polyamide cytotoxicity observed in LNCaP cells cultured with 1 (Fig. 3.3A). A 
previous study with trabectidin, a DNA minor groove alkylator that causes RPB1 
degradation, showed the toxicity induced by the molecule can be reduced by cotreatment 
with the proteasome inhibitor MG132(36).  To evaluate if polyamide-induced toxicity 
was also reducible by proteasomal inhibition we treated LNCaP cells with 2 in the 
presence and absence of MG132.  We developed analog 2 specifically for this application 
because prolonged incubation with MG132 alone is cytotoxic, and conjugation of an aryl 
group to the γ-aminobutyric acid turn have been shown to improve cellular uptake and 
cytotoxicity of polyamides.  Cell viability experiments showed that 2 induced cell death 
more rapidly than 1 without significant change to DNA binding (Fig. S3.2A-B). Cell 
culture experiments revealed coincubation with MG132 reduced cytotoxicity induced by 
2 (Fig. 3.3B) and prevented degradation of RPB1 (Fig. 3.3C).  Polyamide nuclear uptake 
was not affected by MG132 (Fig. S3.2C-D).  In addition, cytotoxicity studies of cells 
treated with UV radiation and α–amanitin have shown increased cellular sensitivity to 
transcription inhibition upon S phase entry(6, 37).  Similarly, 2 was less toxic to LNCaP 
cells arrested in G1/G0 by serum starvation as compared to cells grown in normal media 
(Fig. 3.3D and S3.2E). 
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Accumulation of p53 and expression of p53 targets in the absence of DNA damage. 
Previously published microarray data of LNCaP cells cotreated with DHT and 1 revealed 
the induction of several p53 target genes	 (12). Despite depletion of RPB1, treatment of 
LNCaP cells with 1 alone induced expression of p53 genes that are characteristic of 
genotoxic stress (Fig. 3.4A) (38).  Many of these genes were previously observed to be 
induced in A549 cells treated with polyamide as well as polyamide-alkylator conjugates 
(14, 39). To examine if direct DNA damage was contributing to p53 activity, we looked 
for evidence of DNA damage in LNCaP cells after extended treatment with 1. Alkaline 
comet assay showed no evidence of DNA fragmentation (Fig. 3.4B).  Additionally, 
treatment with 1 did not induce cellular markers of DNA damage including 
phosphorylation of H2A.X, ATM, DNA-PKcs, p53, or Chk2 (Fig. 3.4C). However, 
modest accumulation of p53 and PARP cleavage were observed. This data suggest that 1 
activates p53 through transcriptional inhibition without DNA damage, a mechanism that 
has been observed for non-DNA targeting agents that exert transcriptional stress such as 
the protein kinase inhibitor 5,6-dichlorobenzimidazole (DRB) and α-amanitin(5, 6, 40). 
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Effects of polyamide treatment on prostate cancer xenografts. We recently reported 
the toxicity and pharmacokinetic (PK) profile of 1 in mice (16). Subcutaneous (SC) 
injection of 1 also results in detectable circulation (Fig. S3.3). We thus selected this 
molecule for further testing against xenografts in vivo. Male NSG mice bearing LNCaP 
xenografts were treated with either vehicle or 20nmol (~1 mg/kg) 1 by SC injection once 
every 3 days for a cycle of three injections. At the experimental end point, mice treated 
with 1 had smaller tumors and lower serum PSA as compared to vehicle controls (Fig. 
3.5A-B). Immunohistological analysis of selected tumors showed evidence of cell death 
by TUNEL stain (Fig. 3.5C). While tumor-free NSG mice treated with 1 under this 
regimen showed no signs of distress or weight loss, LNCaP tumor-bearing NSG mice 
exhibited weight loss by the experimental end point (Fig. S3.4). This was accompanied 
by an elevation in serum uric acid that was not observed in either control group (Fig. 
3.5D). 
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3.4 Discussion 
 DNA targeting agents including cisplatin, the anthracyclines, minor groove 
binders and UV radiation have been demonstrated to affect a multitude of DNA 
dependent enzymes such as the RNA polymerases, DNA polymerase, topoisomerases, 
and helicases (21, 27, 28). Our research group and others have used polyamides as 
molecular tools to modulate gene expression programs (12-14, 29). The programmable 
sequence specificity of Py-Im polyamides offers a unique mechanism to target specific 
transcription factor – DNA interfaces and thereby modulate particular gene expression 
pathways.  In previous studies we’ve focused our analysis on specific changes to 
inducible pathways of gene expression. For example, we have shown polyamide 1 affects 
approximately 30% of the DHT-induced transcripts in LNCaP cells, which may result 
from inhibition of the transcription factor AR-DNA interface	 (12). However, the cellular 
cytotoxicity of this polyamide may not be due to only inhibition of DHT-induced gene 
expression since analogs of 1 exhibits toxicity in a variety of cancer cells (19). It is more 
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likely that polyamides perturb a multitude of DNA dependent cellular processes 
(transcription, replication) that contribute to cytotoxicity.  In this study we show that 1 
interferes with RNAP2 elongation resulting in the degradation of RPB1, activation of 
p53, and triggering of apoptosis, without detectable genomic damage. 
Our previous study has shown polyamide 1 decreased the expression of a large 
number of genes in LNCaP cells (12).  To examine the effect of 1 on the transcription 
machinery we performed genome-wide mapping of RNAP2 occupancy by ChIP-seq.  We 
found that while DHT induction increased RNAP2 occupancy at select AR driven genes, 
cotreatment with 1 caused a genome-wide decrease of RNAP2 occupancy across genic 
regions.  The effect was most pronounced at transcription start sites.  Interestingly, 
RNAP2 occupancy at enhancer loci, where the transcription assemblies may be attached 
to via contacts through other proteins, was not significantly affected by polyamide 
treatment.  This suggests polyamide 1 may preferentially affect RNAP2 loading at 
regions where RNAP2 is actively engaged, a mechanism that has been previously 
proposed for the gene regulatory activity of polyamides (41). 
The displacement of RNAP2 from DNA is caused by many DNA damaging 
agents that pose an impediment to RNAP2 elongation, this effect is normally coupled 
with the degradation of large RNAP2 subunit RPB1.  Indeed, the cellular level of RPB1 
in LNCaP cells was found to decrease in both a time- and concentration-dependent 
manner when treated with polyamide 1.   Polyamide 2, a more cytotoxic analog of 1, also 
reduced cellular RPB1 in LNCaP cells and induced cell death.  Cotreatment of 2 with a 
proteasomal inhibitor MG132 was able to prevent the degradation of RPB1 and reduce 
the toxicity of 2 in cell culture.  In addition, the cytotoxic effects of other RNAP2 
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inhibitors were found to be attenuated by preventing S phase entry.  LNCaP cells arrested 
in G0/G1 by serum starvation also exhibited reduced sensitivity to 2 as compared to cells 
grown in normal media.  The finding that cytoxicity is partially rescued by MG132 
treatment and G0/G1 arrest suggests RPB1 degradation contributes to cytotoxicity, 
however, contributions from other DNA dependent processes are not ruled out.  
While transcription inhibition can activate p53 signaling, both events can be 
caused by DNA damage.  Analysis of previously published microarray data revealed the 
induction of several p53 target genes in LNCaP cells cotreated with DHT and 1 (12). 
Further validation of transcript levels of these genes in this study also showed a time 
dependent increase in the expression of GADD45A, MDM2, IGFBP3, P21, BAX and 
DDIT3 (Fig. 3.4A).  Since these genes are also markers of genotoxic stress (38), and were 
found to be induced in A549 cells treated with alkylating polyamide derivatives (39), we 
searched for signs of DNA damage to determine if it was causing transcription inhibition 
and p53 activation.  Interestingly, both comet assay and immunblot analysis of cellular 
DNA damage markers showed no significant signs of DNA damage.  While faint 
phosphorylation of H2A.X was visible, it is likely caused by cellular apoptosis as 
indicated by the concurrent PARP cleavage.  This data is consistent with studies in yeast 
mutants that are hypersensitive to DNA damage which showed no increased sensitivity to 
polyamide treatment, suggesting these reversible DNA binders do not compromise 
genomic integrity (42).  
The activation of p53 by transcription inhibition in the absence of DNA damage 
has been observed for DNA independent inhibitors of RNAP2 such as DRB, alpha-
amanitin, and various RNAP2 targeted antibodies (5, 6, 40).  Distamycin A, the natural 
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product which provided the structural inspiration for Py-Im polyamides, inhibits the 
initiation of RNA synthesis in cell-free assays (43). In cell culture, distamycin also 
induces degradation of RPB1 and activates p53 (44, 45).  However, low antitumor 
potency and poor stability limit its utility.  
To assess the therapeutic potential of polyamide 1 as an antitumor agent, LNCaP 
xenografts in a murine model were treated with 1 or PBS vehicle.   After three rounds of 
treatment, tumor growth was found to be reduced by 64% in the treated group. While 
treatment with 1 alone did not cause changes in animal body weight or obvious signs of 
toxicity in tumor free animals, treatment in tumor bearing animals resulted in weight loss 
after three treatments.  The accompanied elevation in serum uric acid may be an 
indication of tumor lysis syndrome (46) that is associated with rapid tumor cell turnover 
upon polyamide treatment.  We anticipate that Py-Im polyamides could also demonstrate 
efficacy in additional xenograft models. 
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Animal toxicity of hairpin pyrrole-imidazole 
polyamides varies with the turn unit  
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Abstract 
A hairpin pyrrole-imidazole polyamide targeted to the androgen receptor consensus 
half-site (DNA sequence 5’-WGWWCW-3’, W=A or T) was found to exert antitumor 
effects against prostate cancer cells in culture and in xenografts.  Previously, a single 
administration of the compound, hairpin 1, which has a chiral amine at the α position of 
the γ-aminobutyric acid turn (γ-turn) unit, was found to have no adverse effects toward 
wild type mice at 2.5 and 5 mg/kg, however, dose escalation to 10 mg/kg caused 
significant weight loss.  In the same study, hairpin 4, which has an acetamide at the β 
position of the γ-turn unit resulted in increased animal morbidity at 2.3 and 5.4 mg/kg.  
To identify structural motifs that cause animal toxicity in our lead molecule we 
synthesized four polyamides 1-4 with varying amino or acetamide substitution at the α 
and β positions in the -turn unit.  Weight loss, organ histopathology, and serum 
chemistry were analyzed in wild type mice after compound administration.  While serum 
bioavailability was similar for all four polyamides after subcutaneous injection, toxicity 
varied greatly between the four polyamides.  Dose limiting liver toxicity was observed 
for polyamides 1, 2, and 4, but not polyamide 3, with an acetamide at the α position.  
Hairpin 3 demonstrates no significant evidence of rodent toxicity with a single 
subcutaneous injection up to 10 mg/kg, or after repeated dosing at 1 mg/kg by 
histopathology and serum analysis. This compound is cytotoxic to LNCaP cells in cell 
culture and increases p53 activity without inducing detectable DNA damage by comet 
assay, and demonstrates antitumor activity against prostate tumor xenografts at a dose 
level with no detectable pathology. 
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4.1 Introduction 
Prostate cancer is a major contributor of cancer death in American males.(1) The 
malignant transformation of prostate epithelial tissue is caused by an altered pattern of 
gene expression driven by the androgen receptor (AR).  Clinically, localized prostate 
cancer is curable by surgery or radiation.(2, 3) Advanced prostate cancer is treated with 
systemic therapies that target testosterone signaling (enzalutamide, abiraterone), 
immunotherapy (sipuleucel T), and taxane-based chemotherapy (docetaxel, 
cabazitaxel).(4) These new agents have shown survival benefits to patients with 
castration resistant, metastatic disease. However, all patients will eventually progress on 
these drugs. Resistance to the second-generation antiandrogen enzalutamide and the 
CYP17 inhibitor abiraterone may be due to the action of splice variants of AR that lack 
the ligand-binding domain (AR-V).(5, 6)  Therefore, therapy resistant prostate cancer is 
an unmet clinical need, and novel systemic therapies are needed in patients after these 
treatments have failed.(4) 
Direct interference of AR driven transcription at the protein-DNA interface is a 
strategy that can circumvent resistance conferred by AR-V.  Genomic DNA is the 
predominant target of many chemo- and radio- therapies. The interactions of these 
therapies with DNA result in the inhibition of DNA-dependent processes that are over-
active in cancer cells such as transcription.(7-9) While AR driven transcription can be 
inhibited by DNA targeted agents,(10, 11) most conventional DNA-targeted therapeutics 
are genotoxic and can induce secondary malignancies.(12)  DNA-damaging agents may 
also contribute to tumor metastasis through effects on non-cancerous cells in the tumor 
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microenvironment.(13)  Small molecules that interact with DNA without genotoxicity 
could be a significant advance over conventional DNA-targeted therapeutics. 
 Pyrrole (Py) – Imidazole (Im) polyamides are minor groove binders that have 
been shown to affect gene expression in a number of inducible transcription systems. (14-
20)  As non-covalent DNA-binding oligomers, these compounds form specific hydrogen 
bonds to the minor groove floor with programmable sequence recognition and high 
affinity. (21-23) 
 
Py-Im polyamides are toxic to a variety of cancer cell lines, including prostate 
cancer, and exhibit no apparent genotoxicity.(24)  A typical hairpin oligomer consists of 
eight aromatic amino acid rings joined in the middle by a γ-aminobutyric acid (γ-turn). 
(25)  While sequence recognition is predominately directed by the antiparallel pairing of 
N-methylpyrrole and N-methylimidazole carboxamides, structural modifications to the γ-
turn, such as substitution at the prochiral α and β positions, have been shown to influence 
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the DNA affinity,(26) cell uptake, and the biological activity of polyamides in both cell 
culture and animals.(27, 28) 
To date, we have reported the pharmacokinetic (PK) profiles of two eight-ring 
hairpin-polyamides targeted to the sequence 5’-WGWWCW-3’ (W=A or T) in mice.  
The compounds 1 and 4 (Fig. 4.1) differ in structure at the -turn and were found to have 
distinct PK profiles.  Both compounds were bioavailable in serum after intravenous 
injection for more than 24 hours, however 4 was found to have longer retention in both 
the serum and tissues.   Both compounds were minimally excreted through the feces, but 
significant renal clearance was exclusive to 4.(28)  In addition to differences in the PK 
profiles, 1 and 4 also exhibited different degrees of toxicity to female C57BL/6J mice. 
While single subcutaneous administrations of 1 in female mice at 2.5 mg/kg and 5 mg/kg 
did not adversely affect the animals, escalated dosing to 10 mg/kg resulted in weight loss 
greater than 15%.  In comparison, 4 caused acute animal toxicity in addition to weight 
loss at 2.3 mg/kg and 4.5 mg/kg.(28)  To dissect the differences in toxicities, there are 
two variables on the turn that must be sorted out (α versus β position and amino versus 
acetamide substitution). 
More recently compound 1 was found to suppress the growth of LNCaP 
xenografts in immunocompromised mice after three subcutaneous injections at 1 
mg/kg.(24) Thus, a systematic toxicity study of 1 and related polyamides with 
modifications to the γ-turn may yield structures with reduced animal toxicity.  In 
addition, an extensive toxicity study of polyamides in animals to identify target organs of 
pathology is a necessary step towards translation of this technology into the clinic.   
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In this paper, we report the animal toxicity of four structurally related polyamides 
with identical Py-Im sequence but with different substitutions at the γ-turn (Fig. 4.1), a 
change that does not alter binding sequence preference.  We assessed mouse weight, 
organ histopathology, and serum chemistry in wild type male mice after single and 
multiple dosing regimens.  Dose limiting toxicity was observed at the highest dose for 
three of the four molecules. From this study, we have identified one polyamide that 
demonstrates no detectable toxicity by histopathology or serum analysis after single or 
repeated subcutaneous injections. 
4.2 Materials and Methods 
Synthesis of polyamides.  Py-Im polyamides 1-4 and 6-9 were synthesized on Kaiser 
oxime resin (Novabiochem) as previously described.(15, 29)   Complete oligomers were 
cleaved from resin using 3,3’-diamino-N-methyl-dipropylamine and purified by reverse-
phase HPLC in 0.1% aqueous TFA and acetonitrile.(30)  Isophthalic acid and fluorescein 
isothiocyanate conjugates were synthesized as previously described.(31)  Cyclic 
polyamide 5 was synthesized on 2-Chlorotrityl chloride resin (Bachem) as previously 
described.(32)  Deprotection of the γ-turn was performed as described.(26)  Hairpin 
polyamides 3, 4, 8, and 9 were acetylated as previously described.(26, 33)  Polyamides 1-
9 were purified again by reverse phase HPLC after final conjugation. All polyamide 
purity and molecular weight were measured by analytical HPLC and MALDI-ToF mass 
spectrometry, respectively (Table S4.1).   
Chemicals and animals.  Ten percent neutral buffered formalin was purchased from 
Richard-Allan Scientific.  Six to eight week old male C57BL/6J mice were purchased 
from Jackson labs. 
65 
	
	
	
Thermal denaturation assay.  Thermal stabilization of the DNA oligo 5’-
TTGCTGTTCTGCAA-3’ by 1-4 (target sequence underlined) was determined as 
previously described. (26)  
Animal weight loss analysis.  All animal experiments were conducted under an 
approved protocol at the California Institute of Technology.  Animals were allowed to 
adjust for 3 days after arrival before treatment.  Compounds were quantified with a 
UV/Vis spectrophotometer using extinction coefficient of 69500 M−x·cm−c at λmax near 
315 nm.  For single injection weight loss experiments, the animals were separated into 3 
treatment groups receiving 1 mg/kg, 3 mg/kg, or 10 mg/kg of compound in up to 200 μL 
of a 25% DMSO/saline vehicle, with 4 animals per group.   Animals were monitored 
daily for weight loss over 9 days and sacrificed.   For repeated injection experiments the 
animals were separated into groups of 3 and injected with 1 mg/kg of 1-4 once every 3 
days and sacrificed two days after the last injection.  Weight was recorded on days of 
injection and at the experiment endpoint. 
Animal histopathology analysis.  Sacrificed animals from weight loss experiments were 
fixed in 10% formalin and sent for histopathology analysis by IDEXX-RADIL.  
Histopathologic analysis was performed on the cecum, duodenum, heart, ileum, kidney, 
liver, lung, pancreas, spleen, and stomach.  Tissue analysis was performed as a blind 
study to the identity of the animals. 
Serum analysis.  Serum from treated animals were collected by retroorbital bleeding.  
Blood samples were centrifuged at 6,000 rpm for 5 min to collect the serum.  Serum 
ALT, AST, total bilirubin, BUN, and creatinine levels were sent for analysis by IDEXX-
RADIL.  Serum analysis was performed as a blind study to the identity of the animals.  
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For hematology analysis, blood was collected from 5 male C57BL6/J mice by retroorbital 
bleed and sent for hematological analysis in K2EDTA coated BD Microcontainers
TM.  
The animals were allowed to recover for 1 week before treatment with 2 using the same 
injection conditions as the NSG mice.  At the treatment endpoint the animals were bled 
again and euthanized.  Blood samples for serum chemistry analysis and hematology 
analysis were prepared separately.  All samples were sent for analysis at IDEXX-RADIL.  
Liver microsomal stability analysis.  Liver microsomal stability of 1-4 was performed 
by Apredica.  Briefly, each polyamide was incubated with 1 mg/ml human or mouse 
microsomes at 37 oC.  The reaction was incubated in 100 mM KH2PO4, 2mM NADPH, 
3mM MgCl2 at pH 7.4.  Samples were also incubated in the absence of NADPH to detect 
NADPH-free degradation.  After 60 min the samples were mixed with an equal volume 
of ice cold methanol stop solution.  The mixture was allowed to sit on ice for at least 10 
min and mixed with an equal volume of water.  The samples were then centrifuged to 
remove the precipitates and the samples were analyzed by LC/MS/MS.  Data represents 
% remaining by comparing with time zero concentration.  The experiments were 
performed in duplicate. 
Tissue distribution of fluorescein tagged polyamides.  Male C57BL/6J mice (n=2 per 
group) were injected with 50 nmol (~3 mg/kg) of 6-9 and then sacrificed 24 hours later. 
Tissue was excised and processed as previously described. (20)  Fluorescence intensity in 
liver tissue was assessed by laser confocal microscopy in 10 μm thick sections. 
Cell Viability Assays.  LNCaP cells were plated in clear bottom 96-well plates at 5,000–
7,500 cells per well and allowed to adhere for 36–48 h.  Compounds were then added in 
fresh media. Cell metabolic activity was determined by the WST-1 assay (Roche) after 
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72-h incubation with cells.  Quantification was performed on a Perkin Elmer Victor 3 
plate reader.  Assays were performed in biological triplicates. 
Protein ELISA Assays.  Cellular levels of RPB1 and p53 protein in LNCaP cells after 
treatment with 10 M 2 for 72 h were determined by ELISA.  Cells treated with DMSO 
vehicle and 1 M doxorubicin for 24 h were used as control.  Cellular RBP1 levels were 
determined by a RPB1 specific ELISA kit (Cusabio Life Sciences) according to 
manufacturer’s instructions.  Total cellular p53 protein level was determined with a pan-
p53 ELISA kit (Roche) according to manufacturer’s instructions.  Assays were performed 
in biological triplicates. 
Quantitative RT-PCR.  LNCaP cells were plated in 12 well plates at 50,000 cells per 
well and allowed to adhere for 36-48 h.  The cells were then treated with 1, 3, and 10 M 
of 2 for 72 h.  Total cellular RNA was extracted using RNEasy columns (Qiagen) 
following the manufacturer’s protocols. Isolated RNA was reverse transcribed with 
Transcriptor First Strand cDNA kit (Roche). Quantitative real-time PCR was performed 
using SYBR Green PCR Master Mix (Applied Biosystems) on an ABI 7300 instrument. 
Amplification of p21, IGFBP3, and GADD45A cDNA was measured relative to β-
glucuronidase using previously published primers.  Experiments were performed in 
biological replicates.   
Comet Assay.  LNCaP cells were plated in 6 well plates at 100,000 cells per well and 
allowed to adhere for 36–48 h. The cells were then incubated with either 10 μM 2 for 48 
h or 5 μM doxorubicin for 4 h.  DNA damage was assayed using the Trevigen 
CometAssay system.  Cells were harvested by gentle aspiration with PBS and prepared 
on slides according to the manufacturer’s protocol. Comets slides were imaged on a 
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confocal microscope (Exciter, Zeiss) at 10× magnification. Images were scored using 
Comet Assay Lite IV (Perceptive Instruments). More than 100 comets were scored for 
each condition.  DNA damage is reported as percentage of DNA in the tail. 
In Vivo Xenograft Experiments.  Mice experiments were conducted under an approved 
protocol by the Institutional Animal Care and Use Committee of the California Institute 
of Technology. Male C57BL6/J mice and male NSG mice were purchased from The 
Jackson Laboratory. All animals were maintained on a standard light-dark cycle. LNCaP 
cells (2.5 million cells) were engrafted in a mixture of 1:1 media and matrigel in the left 
flank of NSG mice. Tumors were allowed grow to ∼200 mm3 (0.5 × L × W2) before 
treatment.  Py-Im polyamide 2 was administered by SC injection once every 3 d at 1 
mg/kg in a 20% (vol/vol) DMSO:Normal saline vehicle solution for 6 injections.  
Animals were sacrificed two days after the final injection.  Animal weight and general 
health were monitored daily.  Fourteen animals were used for each treatment group. 
4.3 Results  
Selection of polyamides. We synthesized four structurally related polyamides (Fig. 4.1) 
that have an identical Py-Im sequence. These polyamides demonstrate thermal 
stabilization of DNA duplexes containing their target sequence (Fig. S4.1). Polyamide 1, 
ImPyPyPy-2-(R)H2Nγ-ImPyPyPy~NHMe~IPA, suppressed LNCaP xenografts in 
mice.(24)  Polyamide 2, ImPyPyPy-3-(R)H2Nγ-ImPyPyPy~NHMe~IPA, differs from 1 in 
that the γ-turn is substituted at the β position. Polyamide 3, ImPyPyPy-2-(R)AcHNγ-
ImPyPyPy~NHMe~IPA, differs from 1 in that the primary amine is acetylated. 
Polyamide 4, ImPyPyPy-3-(R)AcHNγ-ImPyPyPy~NHMe~IPA, incorporates both changes 
from 2 and 3. Our previous report in female mice showed 1 and 4 both circulated in 
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serum after intravenous injection.(28) To determine if 1-4 demonstrated comparable 
serum levels after subcutaneous injection, male C57BL/6J mice were injected with 10 
mg/kg each of 1-4 and blood collected by retroorbital bleed at various time points. All 
polyamides were bioavailable and detectable up to 24 h after subcutaneous injection (Fig. 
S4.2). 
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Escalating Single Dose Subcutaneous Injections. To determine the acute effects of 
subcutaneous dosing of 1-4 and dose-limiting organ toxicities, 8 week-old male 
C57BL/6J mice (n=4 per dosing group) were treated with 1, 3, 10 mg/kg 1-4 and 
observed for 9 days and then sacrificed (Fig. 4.2). Representative mice (n=2 per dosing 
group unless otherwise noted) were subjected to histopathology analysis by a veterinary 
pathologist. Blood from all mice was sampled and sent for analysis of serum markers of 
target organs. Mice treated with 1 and 2 demonstrated significant weight loss only at 10 
mg/kg. Polyamide 4 was only tolerated at 1 mg/kg; all mice treated with 4 at 3 or 10 
mg/kg exhibited hunched posture, loss of mobility, and acute morbidity.  Mice treated 
with polyamide 2 at 10 mg/kg demonstrated similar morbidity. These mice were 
euthanized when significant duress was apparent. All other mice, including those treated 
with 1 at 10 mg/kg and 3 at all concentrations, demonstrated no change in behavior and 
appearance. 
  Histopathology revealed lesions consistent with toxicity in the liver, kidney and 
spleen in animals receiving a single injection of polyamides 1, 2 and 4.  The most severe 
lesions characterized by diffuse hepatocellular necrosis and apoptosis or multifocal 
bridging hepatocellular necrosis and apoptosis were identified in animals treated with 
polyamide 2 at 10 mg/kg and polyamide 4 at both 3 and 10 mg/kg, respectively.  Mild 
hepatocellular necrosis and apoptosis was observed in animals treated with polyamide 1 
at doses of 3 and 10 mg/kg, polyamide 2 at 3 mg/kg and polyamide 4 at 1 mg/kg (Fig. 
4.3A).  Moderate atypical tubular regeneration (karyomegaly, tubular attenuation, mitotic 
figures) and/or tubular epithelial necrosis and apoptosis were seen in the kidneys in 
animals treated with polyamide 2 at 3 mg/kg and polyamide 4 at 3 and 10 mg/kg (Fig. 
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4.3B).  Milder tubular regeneration and karyomegaly was observed in animals treated 
with polyamide 1 at 10 mg/kg and polyamide 4 at 1 mg/kg.  Mild lymphoid apoptosis in 
the white pulp of the spleen was noted in animals treated with polyamide 2 at 10 mg/kg 
and polyamide 4 at 3 and 10 mg/kg.  Polyamide 3 demonstrated no detectable toxicity at 
any dose level tested.  No lesions consistent with toxicity were observed in the 
gastrointestinal tract, heart, lung, pancreas, or stomach in any animals. 	
Because toxicity to the liver and kidneys were identified as the target organs at 
risk, serum markers for these organ systems were measured (Fig. 4.3C). Mice treated 
with polyamide 1 demonstrated significant elevation of AST, ALT, and total bilirubin at 
10 mg/kg, indicative of acute damage to liver cells, and moderate elevation of ALT at 3 
mg/kg. Elevation of creatinine and blood urea nitrogen (BUN) was not observed for any 
dose level of 1. Polyamide 2 treated mice had severe elevation of AST, ALT, and total 
bilirubin at 10 mg/kg and to a lesser extent at 3 mg/kg. These mice also had elevated 
BUN at 10 mg/kg. Mice treated with polyamide 4 demonstrated marked and severe 
elevations of AST, ALT, and total bilirubin at both 3 mg/kg and 10 mg/kg. In addition, 
these mice had significantly elevated creatinine and BUN at 10 mg/kg, and elevated BUN 
at 3 mg/kg. Mice treated with polyamide 3 demonstrated no elevation of these markers at 
the dose levels tested. 
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In a previous circulation study, it was found that a cyclic form of a hairpin 
polyamide targeted to the sequence 5’-WGGWWW-3’ had increased animal toxicity.(34)  
However, in addition to the motif change from hairpin to cycle, the -turn of the cyclic 
compound was also changed from a (R)-2,4-diaminobutyric acid turn to (R)-3,4-
diaminobutyric acid turn.  To determine if the toxicity is dependent on the polyamide 
shape or the -turn, we synthesized cyclic polyamide 5 (Fig. S4.3).  The compound was 
found to be bioavailable after subcutaneous injection at 10 mg/kg and did not cause 
significant weight loss in animals.  However compound  5 did affect the kidney and liver 
and caused levels of ALT and AST to increase in a dose dependent manner. 
Multiple-Dose Subcutaneous Injections.  In addition to single dose injections, the 
effects of repeated dosing of polyamides 1-4 in mice were examined. In this experiment, 
8 week-old male C57BL/6J mice (n=3 per dosing group) were treated with 1 mg/kg of 
polyamides 1-4 by subcutaneous injection every 3 days, for a cycle of three injections 
and then sacrificed two days after the final injection (Fig. 4.4A). As in the single dosing 
experiments, two mice per group were subjected to histopathology analysis and all blood 
samples were sent for analysis. Mice treated with 1, 2 and 3 demonstrated no loss in 
weight or physical morbidities. Two sequential injections of 4 at 1 mg/kg resulted in 
dramatic weight loss, loss of mobility, and hunched posture within six days (Fig. 4.4B). 
These mice were promptly euthanized. 
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Histopathology of these mice treated with polyamide 1 and 2 revealed mild 
multifocal hepatocellular necrosis and apoptosis in the liver and mild variable tubular 
attenuation, karyomegaly and epithelial necrosis and apoptosis in the kidney.  There was 
marked hepatocellular necrosis and apoptosis in the liver and hyaline droplet 
accumulation in the kidneys of animals treated with polyamide 4 (Fig. 4.4C).  Because 
mice treated with 4 did not tolerate two sequential injections at 1 mg/kg, and single 
dosing resulted in moderate liver and mild kidney damage at 3 mg/kg, we chose not to 
test this compound further. Consistent with the findings on histopathology, mice treated 
with 1 and 2 had elevated AST and ALT (Fig. 4.4D). Mice treated with 3 had no 
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histopathologic lesions consistent with toxicity or alterations in liver and kidney serum 
markers.  
In Vitro Liver Microsomal Stability Assay. Liver pathology was the most striking 
abnormality and was most severe for 4.  To assess if liver pathology was related to the 
stability of these compounds, we investigated the metabolic stability of these polyamides 
to liver microsome isolates. Stability to human and mouse liver microsomes with and 
without NADPH was tested for polyamides 1-4. Polyamide 1-3 all demonstrated high 
stability (>90% intact) after 1 hour incubations (Table S4.2). However, less than 5% of 
polyamide 4 remained intact after 1 hour incubation with either human or mouse liver 
microsomes independent of the presence of NADPH.  
Liver uptake of Fluorescein-Polyamide Conjugates. To determine if the chemical 
modifications of the γ-turn corresponding to 1-4 could influence liver uptake of 
polyamides of otherwise identical structure, we synthesized four polyamide analogous to 
1-4, but with fluorescein isothiocyanate replacing isophthalic acid at the C-terminus (Fig. 
S4.4). Mice treated with FITC-polyamide conjugate 8, which has a γ-turn substitution 
identical to that of 3, demonstrated less nuclear fluorescence in liver sections than the 
other FITC-polyamide conjugates (Fig. S4.5). Mice treated with FITC-polyamide 
conjugate 9, which has the γ-turn corresponding to 4, demonstrated the most intense 
nuclear fluorescence in liver sections. 
Cellular uptake and cytotoxicity.  To determine the biological activity of 3 in LNCaP 
cells we first looked for evidence nuclear localization using fluorescein analog 8.  The 
fluorescein analog of 1, compound 6, was used as benchmark.  Confocal microscopy of 
LNCaP cells incubated with 2 M of 6 or 8 for 24 hr showed robust nuclear localization 
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(Fig. 4.5A).  Viability of LNCaP cells was also reduced in a dose dependent manner by 3, 
with the half maximal inhibitory concentration at 2.1±0.3 M (Fig. 4.5B).   
 
Biological characterization.  Previously we found 1 to affect the RNA polymerase II 
holoenzyme, leading to the degradation of the large subunit, RPB1, and increase cellular 
p53 protein.(24)   Similarly, polyamide 3 reduced RPB1 levels when incubated with 
LNCaP cells at 10M for 72 h (Fig. 4.5C). The level of p53 protein, as well as the 
transcripts of several p53 target genes, was also increased after treatment with 3 (Fig. 
4.5D-E).  In addition, treatment of LNCaP cells with 10 M of 3 for 48 h did not result in 
increased DNA damage by the comet assay (Fig. 4.5F). 
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Antitumor activity.  Next, we tested the activity of 3 against LNCaP xenografts in 
immunocompromised mice.   Male NSG immunocompromised mice were engrafted with 
2.5 million LNCaP cells. When the tumors reached 200 mm3 (0.5 × L × W2) treatment was 
initiated. Mice were treated with either 3 (SC, 1 mg/kg in 20% DMSO/normal saline, 
n=14) or vehicle (20% DMSO/normal saline, n=14) once every three days for a cycle of 
six injections.  The animals were then sacrificed two days after the final injection (Fig. 
4.6A). Both groups of animals demonstrated minimal weight loss and no signs of distress 
during the course of the experiment (Fig. 4.6B).  Mice treated with 3 had smaller tumors 
than those treated with vehicle (T/C = 52.4%) (Fig. 4.6C).  
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 To assess the toxicity of the treatment regimen in healthy animals, male 
C57BL/6J mice were treated with an identical regimen as the tumor-bearing mice and 
were sacrificed two days after the final injection.  Because the liver and kidney were 
identified as the target organs of toxicity in our previous study, we assessed relevant 
serum markers for liver and kidney pathology (Fig. 4.6D). Treated mice demonstrated no 
elevations in AST, ALT, total bilirubin, creatinine, or BUN.  To examine if 3 has an 
effect on circulating blood counts, whole blood was sampled before treatment and at the 
time of sacrifice. No significant hematologic changes were noted for the total white blood 
cell, total red blood cell, hemoglobin, neutrophil, or lymphocyte count (Fig. 4.6E). 
4.4 Discussion 
Py-Im polyamides interfere with DNA-dependent processes, including 
transcription, through non-covalent binding to the minor groove and do not result in 
significant levels of genotoxicity.(24) We believe these characteristics of polyamides 
may represent a significant advance over current DNA-targeted cancer therapies. We 
recently reported antitumor efficacy of polyamide 1 against LNCaP xenografts.(24)  Our 
hypothesis is that a new class of oncologic therapeutics could be developed based on the 
Py-Im polyamide technology platform.  However, a more thorough understanding of the 
effects of selected polyamides in pre-clinical animal models is required. 
Although extensive prior work has demonstrated bioavailability of hairpin 
polyamides in rodents, (28, 35-37) the physiological effects of polyamides in an animal 
model have not been systematically examined. Based on our lead polyamide 1, we 
synthesized three additional polyamides and varied the γ-turn. This chemical change does 
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not alter DNA target sequence, but affects animal toxicity and tissue distribution in 
mice.(28) 
We find that subtle changes to the γ-turn can dramatically impact systemic 
toxicity of the selected polyamides in rodents.  In line with previously published work, 
compound 1 caused weight reduction in animals treated at 10 mg/kg but caused no other 
visible side effects.(28)  Compound 4 lead to pronounced deterioration in the animals’ 
condition at 3 and 10 mg/kg.  Initially, the toxicity associated with compound 4 was 
attributed to the acetylation of the primary amine since acetylation generally leads to 
increased toxicity in cell culture.(27)  However the un-acetylated version of 4, compound 
2, also demonstrated marked toxicity towards the animals while the acetylated version of 
1, compound 3, showed no adverse effects, suggesting the acetylation of the amine is not 
the sole contributor to differences in toxicity.  
 Furthermore, a previous study reported that a cyclic polyamide with a (R)-3,4-
diaminobutyric acid turn was more toxic than its hairpin counterpart, which possessed a 
(R)-2,4-diaminobutyric acid turn.  To see if the cyclic version of 1 lead to increased 
animal toxicity we synthesized 5.  This compound was detectable in the serum after SC 
injection and was found to have less effect on animal weight than 1.  This suggests the 
increase in polyamide induced toxicity is associated with the transition of the (R)-2,4-
diaminobutyric acid turn to the (R)-3,4-diaminobutyric acid turn. 
To identify the cause of animal morbidity we conducted histopathological 
analysis on sacrificed animals.  We found the liver and kidney to be the main organs of 
pathology for compounds 1, 2, 4, and 5.   Compound 3 caused no detectable organ 
damage.  Liver damage was most pronounced for 2 at 10 mg/kg, and 4 at 3 and 10 mg/kg.  
80 
	
	
	
Compound 5 caused moderate damage to both the liver and kidney at 3 and 10 mg/kg.  
We further confirmed our histopathology results with serum measurements of ALT, AST, 
total bilirubin, BUN, and creatinine.  The liver damage markers ALT and AST were 
significantly elevated at higher doses of 1, 2, 4, and 5.  Blood urea nitrogen levels were 
found to be elevated for 2 at 10 mg/kg and 4 at 3 and 10 mg/kg. 
In addition to single dose experiments we also examined the effects of 1-4 on 
animal health after multiple treatments with an injection regimen that was identical to the 
treatment cycle used in our previous xenograft study.(24)  We found compounds 1-3 had 
minimal effect on animal weight over 3 injections of 1 mg/kg, while compound 4 caused 
acute distress in the animals after 2 injections.   Histopathology and serum marker 
analysis was able to detect liver and kidney damage in animals treated with all 
compounds except 3. 
Since the liver is most affected by polyamides, we speculated enzymatic 
degradation of the compounds may contribute to animal toxicity.   To test the stability of 
compounds 1-4 in the liver we conducted microsomal degradation assays with human and 
mice liver microsomes.  Compounds 1-3 was found to be >90% intact after a 60 min 
incubation with 1 mg/ml of microsomes.  Therefore, the reduced liver toxicity by 3 as 
compared to 1, 2, and 4, may not be explained on the basis of differing stability to liver 
microsomes.  Interestingly, while 4 was previously reported to be stable against rat and 
human microsomes,(33) less than 5% of compound 4 was remaining at the end of the 
assay.  This may be explained by the lower amount of enzyme (0.3 mg/ml) used in the 
previous assay.   
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The tissue distribution of Py-Im polyamides is largely affected by structure.  In 
our previous pharmacokinetic study we showed 4 had greater localization to the lung, 
liver, and kidney than 1.  Thus, differences in liver uptake of compounds 1-4 may 
contribute to the differences in animal toxicity.  To visualize nuclear uptake we 
synthesized fluorescein analogues of 1-4.  Of the four compounds, 8 (the fluorescein 
analogue of 3) showed the least amount of nuclear localization, which may explain the 
apparent lack of animal toxicity. 
Polyamide 1 was shown to exert cellular toxicity, in part, through the inhibition of 
transcription.(24)  In line with previous work, polyamide 3, was also found to affect 
cellular level of RPB1 and p53, which suggests the cytotoxic effects of 3 also stems from 
transcription inhibition.  Furthermore, no increased DNA fragmentation was observed 
when cells were treated with 3, indicating the compound interferes with transcription in a 
nongenotoxic manner. 
In addition to exhibiting similar biological activity in cell culture and having 
reduced animal toxicity, 3 also demonstrated antitumor activity towards LNCaP 
xenografts.  Tumor-bearing animals and wild type animals were able to sustain 6 
injections of 3 without showing any signs of duress.  Further characterization of serum 
chemistries and hematology markers indicates compound 3 is well tolerated by the 
animals. 
In conclusion, we have identified a structural motif that affects the animal toxicity 
of Py-Im polyamides.  The transition of the (R)-2,4-diaminobutyric acid turn to a (R)-3,4-
diaminobutyric acid turn significantly increases the animal liver and kidney damage 
caused by polyamides.  Out of the panel of four compounds we have identified 
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polyamide 3, which contains the (R)-2-acetylamino-4-aminobutyric acid turn and 
demonstrates no detectable animal toxicity at 10 mg/kg.  This compound behaves 
similarly to 1 in cell culture, and retains antitumor activity towards LNCaP xenografts.  
This second-generation hairpin polyamide provides a promising lead for the development 
of Py-Im polyamides as anticancer therapeutics. 
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